Summary of project PR000575

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000575. The data can be accessed directly via it's Project DOI: 10.21228/M8BM2Z This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Project ID: PR000575
Project DOI:doi: 10.21228/M8BM2Z
Project Title:Mayo Pilot and Feasibility: Targeting Myelin Metabolism to Enhance Recovery of Function after SCI
Project Summary:The loss of myelin, degeneration of the myelin producing oligodendroglia and impaired remyelination are essential features of traumatic spinal cord injury (SCI) that significantly limit patient recovery of function. The lipid rich composition of myelin, including exceptionally high levels of saturated fatty acids, underlie its essential physiological roles, including its structural and signaling properties and electrical insulation of axons to facilitate the conduction of nerve impulses. The myelin sheaths also provide metabolic support to the axons they wrap, and myelin health is therefore essential to the maintenance of axon integrity and function in the brain and spinal cord. The primary goal of this Pilot Proposal to the Mayo Clinic Metabolomics Core is to integrate highly sensitive metabolomics liquid chromatography-tandem mass spectrometry (LC/MS/MS) assays to quantify the lipid composition of the myelin membrane, with our conventional neurobehavioral approaches, enabling us to explore the metabolic basis of new interventions capable of promoting myelin regeneration and restoration of patient function. Metabolomics Core expertise in Magnetic Resonance Spectroscopy (NMR) based evaluation of key metabolites involved in CNS injury and repair (N-acetyl-L-aspartate, choline, myo-inositol, glucose/ glutamine and lactate) will also be applied to strengthen our mechanistic understanding of myelin injury and repair. Specifically, utilizing these innovative approaches we will test a novel hypothesis driven by new preliminary findings that the levels of dietary fatty acids can be optimized alone, or in combination with exercise training, to facilitate myelin regeneration and recovery of neurobehavioral function after injury to the adult spinal cord. In Aim 1, we will determine whether alterations in dietary fat, including saturated fat or omega-3 fatty acids, facilitate restoration of the myelin membrane and metabolite signatures of central nervous system repair after experimental SCI in adult mice. In Aim 2, we will determine whether exercise training alone or in combination with dietary fatty acid supplementation fosters myelin regeneration and recovery of function after experimental SCI. The proposed studies will leverage the expertise of the Mayo Metabolomics Core with that of Dr. Scarisbrick (Mayo) in myelin biology and Dr. Gomez Pinilla (UCLA) in central nervous system plasticity to investigate whether two highly targetable lifestyle variables, that is diet and exercise, can be modulated to improve myelin metabolism and functional recovery after SCI.
Institute:Mayo Clinic
Last Name:Scarisbrick
First Name:Isobel
Address:200 First St. SW, Rochester, Minnesota, 55905, USA
Email:scarisbrick.isobel@mayo.edu
Phone:507-284-0124

Summary of all studies in project PR000575

Study IDStudy TitleSpeciesInstituteAnalysis
(* : Contains Untargted data)
Release
Date
VersionSamplesDownload
(* : Contains raw data)
ST000792 Large Untargeted Profiling of Myelin to Enhance Recovery of Function after SCI Mus musculus Mayo Clinic MS* 2021-01-19 1 544 Uploaded data (1.3M)
ST000793 Targeted FFA Composition of Myelin to Enhance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-01-19 1 20 Not available
ST000794 Targeted NEFA Panel of Myelin to Enhance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-01-19 1 20 Not available
ST000795 Targeted Cholesterol Profiling of Myelin to Enhance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-01-19 1 20 Not available
ST000796 Targeted Sphingolipids Panel of Myelin to Enhance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-01-19 1 20 Not available
ST000797 Targeted Galactosyl Sphingolipids Concentrations of Myelin to Enhance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-01-19 1 20 Not available
ST000798 Targeted Sphinomyelin Panel of Myelin to Enhance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-01-19 1 20 Not available
ST000799 Targeted TCA Panel of Myelin to Enhance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-01-19 1 19 Not available
ST000848 Targeting Myelin NEFA of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000849 Targeting Myelin FFA Compostion of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000850 Targeting Myelin Cholesterol of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000851 Targeting Myelin Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000852 Targeting Myelin Galactosyl Sphingolipids of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000853 Targeting Myelin Sphinomyelin concentrations of Kallikrein 6 Signals through PAR1 and PAR2 to Enchance Recovery of Function after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000854 Targeted FFA Composition in Kallikrein 6 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 20 Not available
ST000856 Targeted NEFA in Kallikrein 6 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 20 Not available
ST000857 Targeted Cholesterol Profiling of Myelin to Enhance Recovery of Function after SCI. Second Set of Samples Mus musculus Mayo Clinic MS 2021-02-17 1 20 Not available
ST000858 Targeted Sphingolipids in Kallikrein 6 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 20 Not available
ST000859 Targeted Galactosyl Sphingolipid Concentration in Kallikrein 6 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 20 Not available
ST000860 Targeted Sphingomyelin Concentrations in Kallikrein 6 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 20 Not available
ST000861 Targeting Myelin NEFA in PAR1 and PAR2 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000862 Targeting Myelin FFA Compostion in PAR1 and PAR2 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000863 Targeting Myelin Cholesterol in PAR1 and PAR2 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000864 Targeting Myelin Ceramides in PAR1 and PAR2 Mice after SCI Mus musculus Mayo Clinic MS 2021-02-17 1 30 Not available
ST000866 Large Untargeted Profiling in PAR1 and PAR2 Mice after SCI Mus musculus Mayo Clinic MS* 2021-02-17 1 928 Uploaded data (4M)
ST000869 Large Untargeted Profiling in Kallikrein 6 Mice after SCI Mus musculus Mayo Clinic MS* 2021-02-17 1 480 Uploaded data (1.8M)
  logo